3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
fludarabine
63
Cyclophosphamide
63
venetoclax
57
Azacitidine
52
fludarabine phosphate
50
Specimen Handling
44
Whole-Body Irradiation
40
ruxolitinib
37
Mycophenolic Acid
37
Tacrolimus
35
Melphalan
32
Busulfan
32
Biopsy
32
Cytarabine
31
Stem Cell Transplantation
27
Decitabine
27
Granulocyte Colony-Stimulating Factor
21
asciminib
19
decitabine and cedazuridine drug combination
18
Sirolimus
18
Peripheral Blood Stem Cell Transplantation
18
Injections
18
Thiotepa
17
Filgrastim
17
nilotinib
15
X-Rays
14
Methotrexate
14
Cyclosporine
14
Imatinib Mesylate
13
Magnetic Resonance Spectroscopy
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
bexmarilimab
×
Myeloid
×
1 year
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled